- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 14.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 12.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 08.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 08.01. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 03.01. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 22.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 20.12.24 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 18.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 17.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 16.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 15.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 11.12.24 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 11.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 10.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.12.24 | VITA LIFE SCIENCES LIMITED: Profit Guidance | 1 | ASX | ||
| 08.12.24 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,820 | +0,59 % | Green Thumb Industries Inc. to Hold Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 | ||
| INDIVA | 0,016 | 0,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 264,70 | 0,00 % | Alnylam Pharma Anticipates Achieving Non-GAAP Profitability In 2025 | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) anticipates delivering non-GAAP operating income profitability in 2025.Alnylam announced full year 2025 combined net product revenue... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,389 | -1,44 % | Cassava Sciences, Inc.: Cassava Sciences Provides a Business Update | Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,858 | -0,17 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis | SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD... ► Artikel lesen | |
| ADASTRA | 0,193 | -0,52 % | Adastra Holdings Ltd.: Adastra Holdings Confirms Current Management | Langley, British Columbia--(Newsfile Corp. - January 20, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,100 | -1,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome | -- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,983 | +3,58 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,620 | +0,09 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan | CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
| NUMINUS WELLNESS | 0,027 | +3,85 % | Numinus Wellness Inc: Numinus appoints Tan as CEO; Nyquvest becomes chair | ||
| ZELIRA THERAPEUTICS | 0,336 | -0,59 % | ZELIRA THERAPEUTICS LIMITED: Change of Director's Interest Notice x 2 | ||
| OPUS GENETICS | 1,056 | -4,00 % | Opus Genetics, Inc. - 8-K, Current Report | ||
| SOLIGENIX | 2,550 | +1,59 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 56,50 | 0,00 % | ANI Pharma Expects FY24 Adj. EPS, Total Net Revenues To Meet Or Exceed Outlook | WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP), Monday stated that it expects total net revenues, and adjusted earnings per share to be at or above the company's financial outlook for... ► Artikel lesen |
VITA LIFE SCIENCES LIMITED gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.
